1. Home
  2. OLMA vs MGTX Comparison

OLMA vs MGTX Comparison

Compare OLMA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olema Pharmaceuticals Inc.

OLMA

Olema Pharmaceuticals Inc.

HOLD

Current Price

$8.57

Market Cap

949.3M

Sector

Health Care

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$11.06

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLMA
MGTX
Founded
2006
2015
Country
United States
United States
Employees
N/A
393
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
949.3M
1.0B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
OLMA
MGTX
Price
$8.57
$11.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
7
Target Price
★ $44.89
$24.57
AVG Volume (30 Days)
★ 1.0M
842.2K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
15.00
★ 33.02
EPS
N/A
★ 1.30
Revenue
N/A
★ $81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$8.38
Revenue Growth
N/A
★ 144.57
52 Week Low
$6.65
$6.62
52 Week High
$36.26
$15.35

Technical Indicators

Market Signals
Indicator
OLMA
MGTX
Relative Strength Index (RSI) 30.20 30.01
Support Level N/A $8.84
Resistance Level $11.27 $11.85
Average True Range (ATR) 0.59 0.57
MACD -0.13 -0.27
Stochastic Oscillator 8.99 16.88

Price Performance

Historical Comparison
OLMA
MGTX

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: